Fighting against most cancers

In 2012, iTeos spun off from Ludwig Cancer Research and de Duve Institute at UCL to create new drugs educating the immune systems of patients to fight against their cancers. Through a partnership with Pfizer, our first drug is now in clinical trials and iTeos has attracted a team of 40 people with 14 different nationalities to develop the next generation of cancer drugs. Based in Gosselies, iTeos has the ambition to become an world-class player with several new programs in clinical trials within the 3 coming years.